Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized ...

Northwest Biotherapeutics (NWBO) announced the passing of its Senior Vice President and General Counsel, Les Goldman, due to a stroke. Goldman’s duties are being assumed by other members of the ...

Northwest Biotherapeutics Trading Up 0.5% The firm has a market cap of $387.08 million, a price-to-earnings ratio of -3.36 and a beta of -0.81. The business’s 50-day simple moving average is $0. ...

BETHESDA, Md. (AP) — BETHESDA, Md. (AP) — Northwest Biotherapeutics Inc. (NWBO) on Friday reported a loss of $17.9 million in its second quarter. The Bethesda… ...

We are initiating coverage of Northwest Biotherapeutics (OTC BB: NWBO.OB - News) with an Outperform rating. Our 12-month price target is $1.50 per share.

(RTTNews) - Northwest Biotherapeutics (NWBOW) Thursday announced a $5 million convertible note financing and a standby facility for up to $50 million in additional financing.

Review the current Northwest Biotherapeutics Inc (NWBO:PINX) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NWBO is the best investment for you.

Northwest Biotherapeutics fell 19% after the company announced that it had made a direct secondary offering at a price much lower than where the stock closed on Tuesday. The company said that it ...

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.28 and traded ...

(NWBO) on Thursday reported a loss of $15.4 million in its second quarter. The Bethesda, Maryland-based company said it had ...

BETHESDA, Md. (AP) — BETHESDA, Md. (AP) — Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $19.3 million in its first quarter. On a per-share basis, the Bethesda, Maryland ...